Company Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States.
It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301).
It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University.
Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 299 |
| CEO | Gaurav Shah |
Contact Details
Address: 9 Cedarbrook Drive Cranbury, New Jersey 08512 United States | |
| Phone | 609 659 8001 |
| Website | rocketpharma.com |
Stock Details
| Ticker Symbol | RCKT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001281895 |
| CUSIP Number | 77313F106 |
| ISIN Number | US77313F1066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gaurav D. Shah M.D. | Chief Executive Officer and Director |
| Dr. Kinnari Patel M.B.A., Pharm.D. | Head of Research & Development, President and Chief Operating Officer |
| Aaron Ondrey | Chief Financial Officer |
| Martin Louis Wilson J.D. | General Counsel, Chief Compliance Officer and Chief Corporate Officer |
| Dr. Jonathan Schwartz M.D. | Chief Medical and Gene Therapy Officer |
| Meg Dodge | Vice President of Investor Relations and Corporate Communications |
| Isabel Carmona J.D. | Chief People Officer |
| Dr. Gayatri R. Rao J.D., M.D. | Senior Vice President of Clinical Safety and Chief Regulatory Officer |
| Raj Prabhakar M.B.A. | Chief Business Officer |
| Sarbani Chaudhuri M.B.A. | Chief Commercial and Medical Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2025 | 8-K | Current Report |
| Jul 11, 2025 | 8-K | Current Report |
| Jul 3, 2025 | 144 | Filing |
| Jun 18, 2025 | 8-K | Current Report |
| Jun 5, 2025 | SCHEDULE 13G/A | Filing |
| May 27, 2025 | 8-K | Current Report |
| May 20, 2025 | 144 | Filing |
| May 20, 2025 | 144 | Filing |
| May 20, 2025 | 144 | Filing |
| May 20, 2025 | 144 | Filing |